Comment on

• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

  Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L. Yadav M, et al. Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001. Nature. 2014. PMID: 25428506
• Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

  Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Gubin MM, et al. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988. Nature. 2014. PMID: 25428507 Free PMC article.